Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF4, ABBV-368(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ978MR)

This product GTTS-WQ978MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF4 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_003327.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7293
UniProt ID P43489
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF4, ABBV-368(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ978MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13150MR IVTScrip™ mRNA-Anti-NGF, PF-04383119(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PF-04383119
GTTS-WQ4722MR IVTScrip™ mRNA-Anti-IL21, BOS161721(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BOS161721
GTTS-WQ1898MR IVTScrip™ mRNA-Anti-PDCD1, AGEN2034(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA AGEN2034
GTTS-WQ4669MR IVTScrip™ mRNA-Anti-MSTN, BMS-986089(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BMS-986089
GTTS-WQ1742MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ADCT-301
GTTS-WQ14123MR IVTScrip™ mRNA-Anti-PCSK9, aPCSK927(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA aPCSK927
GTTS-WQ2824MR IVTScrip™ mRNA-Anti-NGF, AMG-403(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA AMG-403
GTTS-WQ7049MR IVTScrip™ mRNA-Anti-VEGFA, Fab-12 variant Y0317(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA Fab-12 variant Y0317
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW